Literature DB >> 7766742

Rapid eradication of Helicobacter pylori infection.

G D Bell1, K U Powell, S M Burridge, A F Bowden, W Atoyebi, G H Bolton, P H Jones, C Brown.   

Abstract

BACKGROUND/AIMS: Current Helicobacter pylori eradication therapy for peptic ulcer disease usually involves a 2-week course of either a bismuth preparation or omeprazole in combination with antibiotics. We have studied a shorter, 7-day course of treatment to assess efficacy and tolerability.
METHODS: Four hundred and thirty-six patients, in three non-randomized groups, received omeprazole (40 mg mane), amoxycillin (500 mg t.d.s.) and metronidazole (400 mg t.d.s.): 308 patients received the triple combination for 14 days; 80 patients were treated for 7 days; and 48 patients received omeprazole and amoxycillin for 7 days but metronidazole for only 5 days.
RESULTS: Helicobacter pylori was eradicated in 89.5%, 91.1% and 87.5%, respectively (98.3%, 92.9% and 100% of metronidazole-sensitive isolates and 75.6% and 88.2% of metronidazole-resistant isolates in the first two groups). Side effects were significantly more frequent in patients who received 14 days (49%) compared with 7 days of treatment (33%); only 8/308 and 1/128 patients, respectively, failed to complete the course.
CONCLUSIONS: On the basis of efficacy, tolerability and cost, we conclude that a 7-day course of the omeprazole (40 mg mane), amoxycillin (500 mg t.d.s.) plus metronidazole (400 mg t.d.s.) combination is effective therapy for the eradication of H. pylori.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766742     DOI: 10.1111/j.1365-2036.1995.tb00349.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

Review 1.  Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

Review 2.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

3.  Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Cost of eradication treatment may have been overestimated.

Authors:  N R Waugh
Journal:  BMJ       Date:  1996-09-07

4.  One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.

Authors:  J J Misiewicz; A W Harris; K D Bardhan; S Levi; C O'Morain; B T Cooper; G D Kerr; M F Dixon; H Langworthy; D Piper
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

5.  The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.

Authors:  P Unge; B Jönsson; N O Stålhammar
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

6.  Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.

Authors:  M Sörberg; H Hanberger; M Nilsson; A Björkman; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Helicobacter pylori and radical therapy for peptic ulcer.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1995-11       Impact factor: 2.401

8.  How should we decide on the best regimen for eradicating Helicobacter pylori?

Authors:  V Savarino; S Vigneri
Journal:  BMJ       Date:  1995-09-02

9.  Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis.

Authors:  A Kokkola; H Rautelin; P Puolakkainen; P Sipponen; M Färkkilä; R Haapiainen; T U Kosunen
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

10.  Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Authors:  M J Buckley; H X Xia; D M Hyde; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.